On March 20, the court barred Glenmark from making, marketing or selling anti-diabetes medicines on the ground that it had "prima facie" infringed the patent of US drug major Merck Sharp and Dohme (MSD).

Reacting to the development, shares of the company on Monday opened on a bearish note at Rs 811.10, then fell 4.92 percent to touch an intra-day low of Rs 790.

At the end of Monday's trading session the stock closed at Rs 793.45, down 4.51 per cent on the BSE.

Accordingly, Glenmark's market capitalisation declined by Rs 1,015.15 crore to Rs 21,525.87 crore.

In a regulatory filing on Monday the company said that the "division bench of Delhi high court has injuncted on Monday Glenmark from manufacturing Zita and Zita-met."

However, the injunction is not applicable for the products (zita and zita-met) which are already in market.

Latest News  from Business News Desk